The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth ...

Medicamen Organics Limited has announced impressive financial results for FY25, showcasing strong performance across key ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

Even though the growth of Massachusetts' life sciences industry has slowed down and faces looming federal funding challenges, ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

The beauty industry is undergoing a significant transformation, driven by scientific advances, evolving consumer expectations ...

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

Despite challenges, thematic and sector ETFs can have a meaningful role within an intelligently constructed portfolio.

Since its inception in 1983, DYPU has been a leader in higher education, emphasising research as a cornerstone of learning.

From using infants gut bacteria to protect adults from cancer, to growing rice on the ocean's surface and non-browning bananas - Norwich ...